0000000000181868

AUTHOR

Jurijs Nazarovs

showing 5 related works from this author

Pituispheres Contain Genetic Variants Characteristic to Pituitary Adenoma Tumor Tissue

2020

The most common type of pituitary neoplasms is benign pituitary adenoma (PA). Clinically significant PAs affect around 0.1% of the population. Currently, there is no established human PA cell culture available and when PA tumor cells are cultured they form two distinct types depending on culturing conditions either free-floating aggregates also known as pituispheres or cells adhering to the surface of cell plates and displaying mesenchymal stem-like properties. The aim of this study was to trace the origin of sphere-forming and adherent pituitary cell cultures and characterize the potential use of these surgery derived cell lines as PA model. We carried out a paired-end exome sequencing of …

AdenomaAdult0301 basic medicinetumor sequencingSomatic cellEndocrinology Diabetes and MetabolismPopulationCell030209 endocrinology & metabolismpituitary adenomaPituitary neoplasmBiologylcsh:Diseases of the endocrine glands. Clinical endocrinologyGermlinewhole exome sequencing03 medical and health sciences0302 clinical medicineEndocrinologyBiomarkers TumorTumor Cells CulturedmedicineHumansExomePituitary NeoplasmseducationExome sequencingOriginal Researcheducation.field_of_studylcsh:RC648-665Mesenchymal stem cellpituitary adenoma culturesMiddle AgedPrognosisMolecular biologyGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureCell culturePituitary GlandMutationpituispheresFollow-Up StudiesFrontiers in Endocrinology
researchProduct

Medication for Acromegaly Reduces Expression of MUC16, MACC1 and GRHL2 in Pituitary Neuroendocrine Tumour Tissue

2021

Acromegaly is a disease mainly caused by pituitary neuroendocrine tumor (PitNET) overproducing growth hormone. First-line medication for this condition is the use of somatostatin analogs (SSAs), that decrease tumor mass and induce antiproliferative effects on PitNET cells. Dopamine agonists (DAs) can also be used if SSA treatment is not effective. This study aimed to determine differences in transcriptome signatures induced by SSA/DA therapy in PitNET tissue. We selected tumor tissue from twelve patients with somatotropinomas, with half of the patients receiving SSA/DA treatment before surgery and the other half treatment naive. Transcriptome sequencing was then carried out to identify diff…

Cancer Researchbusiness.industrysomatostatin/dopamine (SSA/DA) therapynext generation sequencing (NGS)medicine.disease_causemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282TranscriptomeExtracellular matrixSomatostatinOncologyDownregulation and upregulationDopamineGene expressionAcromegalyCancer researchMedicineacromegalysomatotropinomabusinessCarcinogenesistranscriptomeOriginal Researchmedicine.drugFrontiers in Oncology
researchProduct

A Case of Stage IV Chromophobe Renal Cell Carcinoma Treated with the Oncolytic ECHO-7 Virus, Rigvir®

2019

Patient: Male, 59 Final Diagnosis: Chromophobe renal cell carcinoma, stage IV Symptoms: Discomfort in the right hypochondrium Medication: Oncolytic virus Rigvir Clinical Procedure: Nephro-adrenalectomy Specialty: Oncology Objective: Unusual or unexpected effect of treatment Background: Renal cell carcinoma is the most commonly diagnosed primary malignant tumor of the kidney in adults, and includes the variant of chromophobe renal cell carcinoma. Despite new targeted therapies that improve progression-free survival (PFS) and overall survival (OS) for early-stage renal cell carcinoma, the 5-year survival for patients with stage IV renal cell carcinoma remains below 10%, and the 50% OS is less…

Malemedicine.medical_specialtymedicine.medical_treatmentChromophobe Renal Cell CarcinomaAdrenal Gland NeoplasmsUrology030204 cardiovascular system & hematologyNephrectomyVirus03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineCarcinomaHumansCarcinoma Renal CellOncolytic VirotherapyKidneybusiness.industryAdrenalectomyAdrenalectomyArticlesGeneral MedicineMiddle Agedmedicine.diseaseKidney NeoplasmsNephrectomyEnterovirus B HumanOncolytic virusOncolytic Virusesmedicine.anatomical_structure030220 oncology & carcinogenesisbusinessAmerican Journal of Case Reports
researchProduct

Evaluation of the Possibility to Detect Circulating Tumor DNA From Pituitary Adenoma

2019

Objective: Circulating free DNA (cfDNA) in general and circulating tumor DNA (ctDNA) in particular is becoming an increasingly used form of liquid biopsy biomarkers. In this study, we are investigating the ability to detect ctDNA from the plasma of pituitary adenoma (PA) patients. Design: Tumor tissue samples were obtained from planed PA resections, before which blood plasma samples were taken. Somatic variants found in PA tissue samples were evaluated in related cfDNA, isolated from plasma samples. Methods: Sanger sequencing, as well as previously obtained whole-exome sequencing data, were used to evaluate somatic variants composition in tumor tissue samples. cfDNA was isolated from the sa…

0301 basic medicineSomatic cellEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpituitary adenomaBiologylcsh:Diseases of the endocrine glands. Clinical endocrinologyDNA sequencing03 medical and health sciencessymbols.namesakeGNAS0302 clinical medicineEndocrinologyBlood plasmaTaqManGNAS complex locusLiquid biopsyOriginal ResearchSanger sequencingcirculating tumor DNAlcsh:RC648-665AmpliconMolecular biology030104 developmental biologybiology.proteinsymbolsnext-generation sequencingcompetitive allele-specific TaqManFrontiers in Endocrinology
researchProduct

Long‐term treatment with the oncolytic ECHO‐7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a his…

2016

Oncolytic virotherapy is a recent addition to cancer treatment. Here, we describe positive treatment outcomes in three patients using Rigvir virotherapy. One of the patients is diagnosed with melanoma stage IV M1c, one with small cell lung cancer stage IIIA, and one with histiocytic sarcoma stage IV. The diagnoses of all patients are verified by histology or cytology. All patients started Rigvir treatment within a few months after being diagnosed and are currently continuing Rigvir treatment. The degree of regression of the disease has been determined by computed tomography. Safety assessment of adverse events graded according to NCI CTCAE did not show any value above grade 1 during Rigvir(…

0301 basic medicineMicrobiology (medical)Oncologymedicine.medical_specialtyPathologymedicine.medical_treatmentHistiocytic sarcomaPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineInternal medicineImmunology and AllergyMedicineVirotherapyAdverse effectProspective cohort studybusiness.industryMelanomaGeneral MedicineImmunotherapymedicine.diseaseOncolytic virus030104 developmental biology030220 oncology & carcinogenesisSmall Cell Lung CarcinomabusinessAPMIS
researchProduct